The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
Dennis McGonagle, Kassem Sharif, Anthony O'Regan, Charlie Bridgewood, Dennis McGonagle, Kassem Sharif, Anthony O'Regan, Charlie Bridgewood
Abstract
Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency states termed primary HLH -with radically different therapy strategies in both situations. COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation. We provide a model for the classification of MAS to stratify the MAS-like presentation in COVID-19 pneumonia and explore the complexities of discerning ARDS from MAS. We discuss the potential impact of timing of anti-cytokine therapy on viral clearance and the impact of such therapy on intra-pulmonary macrophage activation and emergent pulmonary vascular disease.
Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.
Figures
References
- Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. New Engl J Med. 2020
- Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020
- Schulert G.S., Yasin S., Carey B., Chalk C., Do T., Schapiro A.H. Systemic Juvenile Idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol (Hoboken, NJ) 2019;71:1943–1954.
- Martini A.J.A.R. Vol. 12. 2012. Systemic juvenile idiopathic arthritis; pp. 56–59.
- Behrens E.M.J.A.R. Vol. 7. 2008. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? pp. 305–308.
- De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395.
- Feist E., Quartier P., Fautrel B., Schneider R., Sfriso P., Efthimiou P. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668–675.
- Favalli E.G., Ingegnoli F., De Lucia O., Cincinelli G., Cimaz R., Caporali R.J.A.R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev. 2020;102523
- Crayne C.B., Albeituni S., Nichols K.E., Cron R.Q. The immunology of macrophage activation syndrome. Front Immunol. 2019;10 119–119.
- Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–461.
- Carter S.J., Tattersall R.S., Ramanan A.V. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford) 2019;58:5–17.
- Ravelli A., De Benedetti F., Viola S., Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128:275–278.
- Davi S., Consolaro A., Guseinova D., Pistorio A., Ruperto N., Martini A. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–768.
- de Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G.R., Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158–1163.
- Poddighe D., Cavagna L., Brazzelli V., Bruni P., Marseglia G.L.J.A.R. Vol. 13. 2014. A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria; pp. 1142–1148.
- Colafrancesco S., Priori R., Alessandri C., Astorri E., Perricone C., Blank M. Vol. 60. 2014. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia; pp. 177–183.
- Rosário C., Zandman-Goddard G., Meyron-Holtz E.G., D'Cruz D.P., Shoenfeld Y.J.B.M. Vol. 11. 2013. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome; p. 185.
- Sharif K., Vieira Borba V., Zandman-Goddard G., Shoenfeld Y.J.C., E. Immunology . Vol. 191. 2018. Eppur Si Muove: ferritin is essential in modulating inflammation; pp. 149–150.
- Bracaglia C., Prencipe G., De Benedetti F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017;15 5–5.
- Wu C., Chen X., Cai Y., Xia J.A., Zhou X., Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020
- Wan S., Yi Q., Fan S., Lv J., Zhang X., Guo L. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) medRxiv. 2020 2020.02.10.20021832.
- Vastert S.J., Jamilloux Y., Quartier P., Ohlman S., Osterling Koskinen L., Kullenberg T. Anakinra in children and adults with Still's disease. Rheumatology (Oxford) 2019;58 vi9-vi22.
- Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis. ANAJIS trialAnn Rheum Dis. 2011;70:747–754.
- Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet (London, England) 2008;371:998–1006.
- Yokota S., Itoh Y., Morio T., Sumitomo N., Daimaru K., Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with Tocilizumab. J Rheumatol. 2015;42:712–722.
- Yao X.H., Li T.Y., He Z.C., Ping Y.F., Liu H.W., Yu S.C. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49 E009.
- Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76:16–32.
- Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020
- Meduri G.U., Headley S., Kohler G., Stentz F., Tolley E., Umberger R. Vol. 107. 1995. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time; pp. 1062–1073.
- Meduri G.U., Kohler G., Headley S., Tolley E., Stentz F., Postlethwaite A.J.C. Vol. 108. 1995. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome; pp. 1303–1314.
- McGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med. 2006;3
- Grateau G., Hentgen V., Stojanovic K.S., Jeru I., Amselem S., Steichen O. How should we approach classification of autoinflammatory diseases? Nat Rev Rheumatol. 2013;9:624–629.
- Grom A.A. Primary hemophagocytic lymphohistiocytosis and macrophage activation syndrome: the importance of timely clinical differentiation. J Pediatr. 2017;189:19–21. e1.
- Brisse E., Matthys P., Wouters C.H. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016;174:175–187.
- Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. 2020. Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019.
- Kopecky-Bromberg S.A., Martínez-Sobrido L., Frieman M., Baric R.A., Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007;81:548–557.
- Cameron M.J., Kelvin A.A., Leon A.J., Cameron C.M., Ran L., Xu L. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. PLoS One. 2012;7 e45842-e45842.
- Falzarano D., de Wit E., Rasmussen A.L., Feldmann F., Okumura A., Scott D.P. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19:1313–1317.
- Sainz B., Jr., Mossel E.C., Peters C., Garry R.F.J.V. Vol. 329. 2004. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) pp. 11–17.
- Zheng M., Gao Y., Wang G., Song G., Liu S., Sun D. 2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients; pp. 1–3.
- Zhang W., Du R.-H., Li B., Zheng X.-S., Yang X.-L., Hu B. Vol. 9. 2020. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes; pp. 386–389.
- Chen W., Lan Y., Yuan X., Deng X., Li Y., Cai X. Vol. 9. 2020. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity; pp. 469–473.
- Okabayashi T., Kariwa H., Yokota S., Iki S., Indoh T., Yokosawa N. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol. 2006;78:417–424.
- Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M.J.C.S. Vol. 122. 2012. IL-6/IL-6 receptor system and its role in physiological and pathological conditions; pp. 143–159.
- Jones S.A., Richards P.J., Scheller J., Rose-John S.J.J.O.I., C. Research . Vol. 25. 2005. IL-6 transsignaling: the in vivo consequences; pp. 241–253.
- Le T.-T.T., Karmouty-Quintana H., Melicoff E., Le T.-T.T., Weng T., Chen N.-Y. Blockade of IL-6 <em>trans</em> Signaling attenuates pulmonary fibrosis. J Immunol. 2014;193:3755–3768.
- Scheller J., Ohnesorge N., Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol. 2006;63:321–329.
- Garbers C., Rose-John S. Dissecting Interleukin-6 classic- and trans-signaling in inflammation and cancer. Methods Mol Biol (Clifton, NJ) 2018;1725:127–140.
- Velazquez-Salinas L., Verdugo-Rodriguez A., Rodriguez L.L., Borca M.V. Vol. 10. 2019. The role of interleukin 6 during viral infections; p. 1057.
- Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020
- Baden L.R., Rubin E.J. Covid-19 — the search for effective therapy. New Engl J Med. 2020
- Bracaglia C., Caiello I., De Graaf K., D'Ario G., Guilhot F., Ferlin W. Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model. Pediatr Rheumatol Online J. 2014;12 O3-O3.
- Vallurupalli M., Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019;134:1783–1786.
- Dinarello C.A. Targeting interleukin 18 with interleukin 18 binding protein. Ann Rheum Dis. 2000;59(Suppl. 1):i17–i20.
- Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475.
- Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020
- Registry C.C.T. 2020. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)
- Gupta S., Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features. Pathogen Ther. 2010;6:137–154.
- Le T.-T.T., Karmouty-Quintana H., Melicoff E., Le T.-T.T., Weng T., Chen N.-Y. Vol. 193. 2014. Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis; pp. 3755–3768.
- Dosch S.F., Mahajan S.D., Collins A.R.J.V. Vol. 142. 2009. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro; pp. 19–27.
- Wang W., Ye L., Ye L., Li B., Gao B., Zeng Y. Vol. 128. 2007. Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway; pp. 1–8.
- Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K. Vol. 19. 2016. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice; pp. 181–193.
- Dienz O., Rud J.G., Eaton S.M., Lanthier P.A., Burg E., Drew A. Vol. 5. 2012. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung; pp. 258–266.
- Yang M.-L., Wang C.-T., Yang S.-J., Leu C.-H., Chen S.-H., Wu C.-L. Vol. 7. 2017. IL-6 ameliorates acute lung injury in influenza virus infection; pp. 1–11.
- Murphy E.A., Davis J.M., Brown A.S., Carmichael M.D., Ghaffar A., Mayer E.P.J.J. Effect of IL-6 deficiency on susceptibility to HSV-1 respiratory infection and intrinsic macrophage antiviral resistance. 2008;28:589–596.
- Bhargava R., Janssen W., Altmann C., Andrés-Hernando A., Okamura K., Vandivier R.W. Vol. 8. 2013. Intratracheal IL-6 protects against lung inflammation in direct, but not indirect, causes of acute lung injury in mice.
- Voiriot G., Razazi K., Amsellem V., Van Nhieu J.T., Abid S., Adnot S. Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury. 2017;18:64.
- Ladel C.H., Blum C., Dreher A., Reifenberg K., Kopf M., S.J.I. Kaufmann and immunity . Vol. 65. 1997. Lethal tuberculosis in interleukin-6-deficient mutant mice; pp. 4843–4849.
- van der Poll T., Keogh C.V., Guirao X., Buurman W.A., Kopf M., Lowry S.F.J.J. Vol. 176. 1997. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia; pp. 439–444.
- Cenci E., Mencacci A., Casagrande A., Mosci P., Bistoni F., Romani L.J.T.J. Vol. 184. 2001. Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis; pp. 610–617.
- Kobayashi T., Tanaka K., Fujita T., Umezawa H., Amano H., Yoshioka K. Vol. 16. 2015. Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis; p. 99.
- Ibrahim Y.F., Moussa R.A., Bayoumi A.M., Ahmed A.-S.F.J.I. Vol. 28. 2020. Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein; pp. 215–230.
Source: PubMed